Seul Ki Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Seul Ki Kim has a total of 167 co-authors. Here are the top co-authors by number of shared publications:
- Byung Chul Jee
Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
33 shared publications - Jung Ryeol Lee
Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Republic of Korea
27 shared publications Seok Hyun Kim
Department of Obstetrics and Gynecology, Seoul National University College of Medicine Seoul, Korea
23 shared publicationsChang Suk Suh
Department of Obstetrics and Gynecology, Seoul National University College of Medicine Seoul, Korea
21 shared publications- Seok Hyun Kim
Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea
14 shared publications Jung Ryeol Lee
Department of Obstetrics and Gynecology, Seoul National University College of Medicine Seoul, Korea
12 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by The Korean Society for Reproductive Medicine in Clinical and Experimental Reproductive Medicine
Beyond body mass index: A contemporary review of obesity and female infertility
Obesity is increasingly understood as a reproductive-metabolic condition that can affect female fertility across the continuum from natural conception to assisted reproductive technology (ART). Excess adiposity may disrupt hypothalamic-pituitary-ovarian regulation, insulin signaling, inflammatory pathways, ovarian function, oocyte competence, embryo development, and endometrial receptivity. This review synthesizes current evidence linking obesity with infertility, reduced ART efficiency, implantation failure, miscarriage, and reduced live birth, while emphasizing that these associations vary according to reproductive and metabolic phenotype. Particular attention is given to polycystic ovary syndrome, advanced age, diminished ovarian reserve, recurrent implantation failure, and recurrent pregnancy loss. Pre-treatment weight-loss strategies, including lifestyle intervention, glucagon-like peptide-1 receptor agonists, tirzepatide, and bariatric surgery, are also considered in relation to reproductive benefit, treatment delay, and pregnancy safety. Overall, obesity should not be treated simply as a body mass index category, but rather as a phenotype-dependent reproductive-metabolic condition that requires individualized fertility-treatment planning.
- 8 October 2026
- Published by The Korean Society for Reproductive Medicine in Clinical and Experimental Reproductive Medicine
Open AccessBeyond body mass index: A contemporary review of obesity and female infertility
Obesity is increasingly understood as a reproductive-metabolic condition that can affect female fertility across the continuum from natural conception to assisted reproductive technology (ART). Excess adiposity may disrupt hypothalamic-pituitary-ovarian regulation, insulin signaling, inflammatory pathways, ovarian function, oocyte competence, embryo development, and endometrial receptivity. This review synthesizes current evidence linking obesity with infertility, reduced ART efficiency, implantation failure, miscarriage, and reduced live birth, while emphasizing that these associations vary according to reproductive and metabolic phenotype. Particular attention is given to polycystic ovary syndrome, advanced age, diminished ovarian reserve, recurrent implantation failure, and recurrent pregnancy loss. Pre-treatment weight-loss strategies, including lifestyle intervention, glucagon-like peptide-1 receptor agonists, tirzepatide, and bariatric surgery, are also considered in relation to reproductive benefit, treatment delay, and pregnancy safety. Overall, obesity should not be treated simply as a body mass index category, but rather as a phenotype-dependent reproductive-metabolic condition that requires individualized fertility-treatment planning.
- Open Access
- 21 January 2026
- Published by The Korean Society for Reproductive Medicine in Clinical and Experimental Reproductive Medicine
- Vol. 53 (3) , 219-225
Average oocyte quality index as a method for scoring dysmorphic oocytes in women with ovarian endometrioma undergoing in vitro fertilization and its correlation with ovarian reserve
Objective: This study investigated whether the average oocyte quality index (AOQI), used as a dysmorphic oocyte scoring system, is higher in women with ovarian endometrioma than in those with unexplained infertility or diminished ovarian reserve (DOR).Methods: We included 92 intracytoplasmic sperm injection cycles in which one to five metaphase II oocytes were obtained, and the AOQI was calculated in each cycle. Cycles were grouped according to the indication for in vitro fertilization: current or recurrent endometrioma (34 cycles), unexplained infertility (26 cycles), and DOR (32 cycles). DOR was defined by a serum anti-Müllerian hormone (AMH) level <1.0 ng/mL. The AOQI was compared among the three groups, and the relationship between serum AMH levels and AOQI was also analyzed.Results: The median AOQI value was significantly higher in the endometrioma group (1.50) compared to the unexplained infertility group (1.00) (p=0.037), but not compared to the DOR group (1.42). Overall, serum AMH level showed an inverse correlation with the AOQI (r=–0.242, p=0.02). Serum AMH level was also inversely correlated with the AOQI in the endometrioma group (r=–0.429, p=0.011), but not in the unexplained infertility and DOR groups. Multiple linear regression analysis demonstrated that serum AMH levels remained inversely correlated with the AOQI (B=–0.176; 95% confidence interval, –0.327 to –0.024; p=0.024), whereas the presence of endometrioma was not a significant factor.Conclusion: The AOQI in the ovarian endometrioma group was higher compared to the unexplained infertility group, and this difference appeared to arise primarily from reduced ovarian reserve rather than the direct impact of endometrioma itself. Serum AMH levels showed an inverse correlation with AOQI, emphasizing the central role of ovarian reserve in determining oocyte quality.
- 21 January 2026
- Published by The Korean Society for Reproductive Medicine in Clinical and Experimental Reproductive Medicine
- Vol. 53 (3) , 219-225
Open AccessAverage oocyte quality index as a method for scoring dysmorphic oocytes in women with ovarian endometrioma undergoing in vitro fertilization and its correlation with ovarian reserve
Objective: This study investigated whether the average oocyte quality index (AOQI), used as a dysmorphic oocyte scoring system, is higher in women with ovarian endometrioma than in those with unexplained infertility or diminished ovarian reserve (DOR).Methods: We included 92 intracytoplasmic sperm injection cycles in which one to five metaphase II oocytes were obtained, and the AOQI was calculated in each cycle. Cycles were grouped according to the indication for in vitro fertilization: current or recurrent endometrioma (34 cycles), unexplained infertility (26 cycles), and DOR (32 cycles). DOR was defined by a serum anti-Müllerian hormone (AMH) level <1.0 ng/mL. The AOQI was compared among the three groups, and the relationship between serum AMH levels and AOQI was also analyzed.Results: The median AOQI value was significantly higher in the endometrioma group (1.50) compared to the unexplained infertility group (1.00) (p=0.037), but not compared to the DOR group (1.42). Overall, serum AMH level showed an inverse correlation with the AOQI (r=–0.242, p=0.02). Serum AMH level was also inversely correlated with the AOQI in the endometrioma group (r=–0.429, p=0.011), but not in the unexplained infertility and DOR groups. Multiple linear regression analysis demonstrated that serum AMH levels remained inversely correlated with the AOQI (B=–0.176; 95% confidence interval, –0.327 to –0.024; p=0.024), whereas the presence of endometrioma was not a significant factor.Conclusion: The AOQI in the ovarian endometrioma group was higher compared to the unexplained infertility group, and this difference appeared to arise primarily from reduced ovarian reserve rather than the direct impact of endometrioma itself. Serum AMH levels showed an inverse correlation with AOQI, emphasizing the central role of ovarian reserve in determining oocyte quality.
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Menopausal Medicine
- Vol. 32
Estetrol (E4): A Comprehensive Review of Its Clinical Implications in Menopausal Medicine
Sinha S, et al. J Menopausal Med. 2026 ;32:e13. https://doi.org/10.6118/jmm.26004
- 1 January 2026
- Published by XMLink in Journal of Menopausal Medicine
- Vol. 32
Open AccessEstetrol (E4): A Comprehensive Review of Its Clinical Implications in Menopausal Medicine
Sinha S, et al. J Menopausal Med. 2026 ;32:e13. https://doi.org/10.6118/jmm.26004
- Open Access
- 30 December 2025
- Published by The Korean Society for Reproductive Medicine in Clinical and Experimental Reproductive Medicine
Comprehensive review of international guidelines on subclinical hypothyroidism and thyroid autoimmunity in infertile women
Thyroid disorders, particularly subclinical hypothyroidism (SCH) and thyroid autoimmunity (TAI), are prevalent among infertile women and may adversely influence assisted reproductive technology outcomes. Multiple international societies have published clinical guidelines addressing these conditions; however, important discrepancies persist regarding screening strategies, thyroid-stimulating hormone (TSH) thresholds, and treatment indications. This review compares recent recommendations from the Korean Thyroid Association (KTA 2023), the American Society for Reproductive Medicine (ASRM 2024), the European Thyroid Association (ETA 2021), and the European Society of Human Reproduction and Embryology (ESHRE 2023). Similarities include targeted screening in high-risk populations and levothyroxine treatment for overt hypothyroidism and selected high-risk SCH cases, whereas key differences relate to TSH cutoff values and the management of SCH in the presence of TAI. Recognition of these inter-guideline differences is necessary to support the development of standards tailored to specific countries, healthcare systems, or institutional practices.
- 30 December 2025
- Published by The Korean Society for Reproductive Medicine in Clinical and Experimental Reproductive Medicine
Open AccessComprehensive review of international guidelines on subclinical hypothyroidism and thyroid autoimmunity in infertile women
Thyroid disorders, particularly subclinical hypothyroidism (SCH) and thyroid autoimmunity (TAI), are prevalent among infertile women and may adversely influence assisted reproductive technology outcomes. Multiple international societies have published clinical guidelines addressing these conditions; however, important discrepancies persist regarding screening strategies, thyroid-stimulating hormone (TSH) thresholds, and treatment indications. This review compares recent recommendations from the Korean Thyroid Association (KTA 2023), the American Society for Reproductive Medicine (ASRM 2024), the European Thyroid Association (ETA 2021), and the European Society of Human Reproduction and Embryology (ESHRE 2023). Similarities include targeted screening in high-risk populations and levothyroxine treatment for overt hypothyroidism and selected high-risk SCH cases, whereas key differences relate to TSH cutoff values and the management of SCH in the presence of TAI. Recognition of these inter-guideline differences is necessary to support the development of standards tailored to specific countries, healthcare systems, or institutional practices.
- Open Access
- 1 December 2025
- Published by The Korean Society for Reproductive Medicine in Clinical and Experimental Reproductive Medicine
- Vol. 52 (4) , 359-366
The role of mammalian target of rapamycin inhibitors in mitigating cyclophosphamide-induced ovarian damage in a murine model
Objective: This study aimed to determine whether pre-treatment with everolimus or rapamycin could prevent ovarian follicle damage induced by cyclophosphamide (Cp).Methods: A total of 120 female BDF-1 mice were randomly assigned into four groups receiving specific treatments. The control group received normal saline on days 1, 3, 5, and 13. The Cp group received saline on days 1, 3, and 5, followed by Cp administration on day 13. The everolimus+Cp group was given everolimus on days 1, 3, and 5, then Cp on day 13. Similarly, the rapamycin+Cp group received rapamycin on days 1, 3, and 5, followed by Cp on day 13. On day 20, all mice were euthanized, ovaries were harvested for histological analysis, and protein expression levels of B-cell lymphoma-extra large (BCL-xL), caspase 3, and mammalian target of rapamycin were evaluated by Western blot analysis.Results: The number of primordial follicles was lower in the Cp group than in the control group. The everolimus group and the rapamycin group also showed reduced primordial follicle counts. No significant differences were observed in the proportions of G1 primordial or G1 secondary follicles among the groups. Compared to the control group, the Cp group and the everolimus group showed lower proportions of G1 primary follicles. However, the rapamycin group had a G1 primary follicle proportion similar to that of the control group. The Cp, everolimus, and rapamycin groups exhibited lower proportions of G1 antral follicles than the control group.Conclusion: Pre-treatment with rapamycin preserved the proportion of G1 primary follicles; however, neither everolimus nor rapamycin preserved the primordial follicle counts.
- 1 December 2025
- Published by The Korean Society for Reproductive Medicine in Clinical and Experimental Reproductive Medicine
- Vol. 52 (4) , 359-366
Open AccessThe role of mammalian target of rapamycin inhibitors in mitigating cyclophosphamide-induced ovarian damage in a murine model
Objective: This study aimed to determine whether pre-treatment with everolimus or rapamycin could prevent ovarian follicle damage induced by cyclophosphamide (Cp).Methods: A total of 120 female BDF-1 mice were randomly assigned into four groups receiving specific treatments. The control group received normal saline on days 1, 3, 5, and 13. The Cp group received saline on days 1, 3, and 5, followed by Cp administration on day 13. The everolimus+Cp group was given everolimus on days 1, 3, and 5, then Cp on day 13. Similarly, the rapamycin+Cp group received rapamycin on days 1, 3, and 5, followed by Cp on day 13. On day 20, all mice were euthanized, ovaries were harvested for histological analysis, and protein expression levels of B-cell lymphoma-extra large (BCL-xL), caspase 3, and mammalian target of rapamycin were evaluated by Western blot analysis.Results: The number of primordial follicles was lower in the Cp group than in the control group. The everolimus group and the rapamycin group also showed reduced primordial follicle counts. No significant differences were observed in the proportions of G1 primordial or G1 secondary follicles among the groups. Compared to the control group, the Cp group and the everolimus group showed lower proportions of G1 primary follicles. However, the rapamycin group had a G1 primary follicle proportion similar to that of the control group. The Cp, everolimus, and rapamycin groups exhibited lower proportions of G1 antral follicles than the control group.Conclusion: Pre-treatment with rapamycin preserved the proportion of G1 primary follicles; however, neither everolimus nor rapamycin preserved the primordial follicle counts.
- Open Access
- 1 January 2025
- Published by XMLink in Journal of Menopausal Medicine
- Vol. 31 (3) , 177-180
A New Transvaginal Operative Technique for Uterine Prolapse and Vaginal Laxity Using a Novel Silicone Implant
Jung YJ, et al. J Menopausal Med. 2025 Nov;31:e7. https://doi.org/10.6118/jmm.25110
- 1 January 2025
- Published by XMLink in Journal of Menopausal Medicine
- Vol. 31 (3) , 177-180
Open AccessA New Transvaginal Operative Technique for Uterine Prolapse and Vaginal Laxity Using a Novel Silicone Implant
Jung YJ, et al. J Menopausal Med. 2025 Nov;31:e7. https://doi.org/10.6118/jmm.25110
- Open Access
- 2 October 2024
- Published by Galenos Yayinevi in Diagnostic and Interventional Radiology
- Vol. 31 (3) , 249-252
Long-term outcomes of catheter-directed sclerotherapy for ovarian endometrioma
Long-term outcomes of catheter-directed sclerotherapy for ovarian endometrioma - Diagnostic and Interventional Radiology
- 2 October 2024
- Published by Galenos Yayinevi in Diagnostic and Interventional Radiology
- Vol. 31 (3) , 249-252
Open AccessLong-term outcomes of catheter-directed sclerotherapy for ovarian endometrioma
Long-term outcomes of catheter-directed sclerotherapy for ovarian endometrioma - Diagnostic and Interventional Radiology
- Open Access
- 1 June 2024
- Published by The Korean Society for Reproductive Medicine in Clinical and Experimental Reproductive Medicine
- Vol. 51 (2) , 163-169
Prevalence and confounders of chronic endometritis diagnosed using CD138 in patients with recurrent implantation failure
Objective: This retrospective study aimed to investigate the prevalence of chronic endometritis, diagnosed using CD138 immunohistochemistry, among infertile women and to assess the association between chronic endometritis and recurrent implantation failure (RIF).Methods: In total, 266 patients who underwent hysteroscopy due to infertility between 2019 and 2020 were included in the analysis. Of these, 136 patients with RIF and 130 non-RIF patients were included in the study. CD138 immunohistochemistry test results, blood biomarkers (including natural killer cells, white blood cells, and the lymphocyte-to-neutrophil ratio), and data on pregnancy outcomes were obtained. If the CD138 test yielded a positive result, the patients received antibiotic treatment.Results: The overall proportion of CD138-positive patients was 32.7% (87/266). The CD138 positivity rate was not related to the number of cycles with implantation failure. In the RIF patient group, no significant associations were found between CD138 positivity and peripheral blood markers. The clinical pregnancy rates were similar between infertile women treated with antibiotics for chronic endometritis and those without chronic endometritis.Conclusion: To improve the pregnancy rate in infertile patients, it may be helpful to combine CD138 testing with other laboratory tests and administer antibiotic treatment if the result is positive.
- 1 June 2024
- Published by The Korean Society for Reproductive Medicine in Clinical and Experimental Reproductive Medicine
- Vol. 51 (2) , 163-169
Open AccessPrevalence and confounders of chronic endometritis diagnosed using CD138 in patients with recurrent implantation failure
Objective: This retrospective study aimed to investigate the prevalence of chronic endometritis, diagnosed using CD138 immunohistochemistry, among infertile women and to assess the association between chronic endometritis and recurrent implantation failure (RIF).Methods: In total, 266 patients who underwent hysteroscopy due to infertility between 2019 and 2020 were included in the analysis. Of these, 136 patients with RIF and 130 non-RIF patients were included in the study. CD138 immunohistochemistry test results, blood biomarkers (including natural killer cells, white blood cells, and the lymphocyte-to-neutrophil ratio), and data on pregnancy outcomes were obtained. If the CD138 test yielded a positive result, the patients received antibiotic treatment.Results: The overall proportion of CD138-positive patients was 32.7% (87/266). The CD138 positivity rate was not related to the number of cycles with implantation failure. In the RIF patient group, no significant associations were found between CD138 positivity and peripheral blood markers. The clinical pregnancy rates were similar between infertile women treated with antibiotics for chronic endometritis and those without chronic endometritis.Conclusion: To improve the pregnancy rate in infertile patients, it may be helpful to combine CD138 testing with other laboratory tests and administer antibiotic treatment if the result is positive.
- Open Access
- 21 March 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (6) , 1807
Surgical and Fertility Outcomes of Reduced-Port Robotic Myomectomy: A Single-Center Experience of 401 Cases
Background: Reduced-port robotic myomectomy (RPRM) using Da Vinci® Xi™ is a good fertility-saving surgical option, but the surgical and fertility outcomes are unknown. Methods: This was a retrospective cohort study evaluating the feasibility of RPRM in an academic tertiary hospital setting. A total of 401 patients who underwent RPRM by a single operator between October 2017 and October 2021 were included. For RPRM, three ports are required: a 1.5 cm umbilical incision and two 0.8 cm incisions 8 cm lateral to the umbilicus. A single-port system was applied through the umbilicus, which also functioned as a working port. Unlike conventional robotic surgery, only three robot arms were utilized for the entire surgical procedure. Results: Surgical and fertility outcomes were assessed through medical records review and follow-up telephone contact. The mean age of patients at the time of surgery was 39.7 ± 6.0 years. The most common indication for surgery was menorrhagia (n = 128, 31.9%). The average number of myomas removed was 4.7 ± 4.1 (1–22), and the size was 7.8 ± 2.5 cm (2.5–16.0). The mean operation time was 103.7 ± 45.6 min. Postoperative complications were found in 9.7% (n = 39) of patients; the most common complication was transfusion (7.7%, n = 31). After surgery, 70 patients tried to conceive, and 56 became pregnant naturally or by assisted reproduction (56/70, 80.0%). The mean interval time from operation to conception was 13.5 ± 10.1 months. Among 56 who conceived, 44 gave birth (62.9%), five were still ongoing (7.1%), and seven had miscarriages (10.0%). Cesarean section was performed for most cases (43/44, 97.7%). Eight patients had obstetric complications (16.3%), but no uterine rupture was reported. Conclusions: RPRM, which provides the benefits of conventional robotic surgery along with favorable obstetric and cosmetic results, is a feasible option for patients with symptomatic uterine myomas who wish to conceive in the future.
- 21 March 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (6) , 1807
Open AccessSurgical and Fertility Outcomes of Reduced-Port Robotic Myomectomy: A Single-Center Experience of 401 Cases
Background: Reduced-port robotic myomectomy (RPRM) using Da Vinci® Xi™ is a good fertility-saving surgical option, but the surgical and fertility outcomes are unknown. Methods: This was a retrospective cohort study evaluating the feasibility of RPRM in an academic tertiary hospital setting. A total of 401 patients who underwent RPRM by a single operator between October 2017 and October 2021 were included. For RPRM, three ports are required: a 1.5 cm umbilical incision and two 0.8 cm incisions 8 cm lateral to the umbilicus. A single-port system was applied through the umbilicus, which also functioned as a working port. Unlike conventional robotic surgery, only three robot arms were utilized for the entire surgical procedure. Results: Surgical and fertility outcomes were assessed through medical records review and follow-up telephone contact. The mean age of patients at the time of surgery was 39.7 ± 6.0 years. The most common indication for surgery was menorrhagia (n = 128, 31.9%). The average number of myomas removed was 4.7 ± 4.1 (1–22), and the size was 7.8 ± 2.5 cm (2.5–16.0). The mean operation time was 103.7 ± 45.6 min. Postoperative complications were found in 9.7% (n = 39) of patients; the most common complication was transfusion (7.7%, n = 31). After surgery, 70 patients tried to conceive, and 56 became pregnant naturally or by assisted reproduction (56/70, 80.0%). The mean interval time from operation to conception was 13.5 ± 10.1 months. Among 56 who conceived, 44 gave birth (62.9%), five were still ongoing (7.1%), and seven had miscarriages (10.0%). Cesarean section was performed for most cases (43/44, 97.7%). Eight patients had obstetric complications (16.3%), but no uterine rupture was reported. Conclusions: RPRM, which provides the benefits of conventional robotic surgery along with favorable obstetric and cosmetic results, is a feasible option for patients with symptomatic uterine myomas who wish to conceive in the future.
- Open Access
- 5 March 2024
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2024 (3) , rjae189
An 8-mm trocar-site hernia at a drainage insertion site after a three-port robotic myomectomy: case report and review of literature
Trocar site hernia is a rare, serious operation-related complication after robotic gynecologic surgery. Here, we present two 8-mm port-site hernia cases after three-port robotic myomectomy with a review of reported previous cases. In the first case, small bowel obstruction was found postoperatively due to herniation at the left mid-axillary line 8-mm trocar site. Small bowel herniation through the same site as the first case was found in the second case. Emergency exploration was performed in both cases by extending the left trocar site. There was no sign of bowel ischemia, and successful bowel reduction and hernia repair were done. Unlike previously reported cases, these cases occurred in a normal body mass index (BMI) patient (first case 20.28 kg/m2, second case BMI 24.80 kg/m2) and were pelvic drain insertion sites. These sites were the weak points of the abdominal muscle coverage. Therefore, the closure of 8-mm trocar sites should be considered.
- 5 March 2024
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2024 (3) , rjae189
Open AccessAn 8-mm trocar-site hernia at a drainage insertion site after a three-port robotic myomectomy: case report and review of literature
Trocar site hernia is a rare, serious operation-related complication after robotic gynecologic surgery. Here, we present two 8-mm port-site hernia cases after three-port robotic myomectomy with a review of reported previous cases. In the first case, small bowel obstruction was found postoperatively due to herniation at the left mid-axillary line 8-mm trocar site. Small bowel herniation through the same site as the first case was found in the second case. Emergency exploration was performed in both cases by extending the left trocar site. There was no sign of bowel ischemia, and successful bowel reduction and hernia repair were done. Unlike previously reported cases, these cases occurred in a normal body mass index (BMI) patient (first case 20.28 kg/m2, second case BMI 24.80 kg/m2) and were pelvic drain insertion sites. These sites were the weak points of the abdominal muscle coverage. Therefore, the closure of 8-mm trocar sites should be considered.